Aethlon Medical Inc
NASDAQ:AEMD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.38
60.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Aethlon Medical Inc
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Cost Reductions: Operating expenses dropped by 48% year-over-year, reflecting lower payroll, fewer bonuses, and reduced trial and admin costs.
Cash Position: The company ended the quarter with about $5.8 million in cash.
Clinical Progress: The Australian oncology trial completed Cohort 1 with no serious safety issues and is moving to Cohort 2, though enrollment is slow.
Trial Results: Early data showed decreases in targeted cancer markers (EVs and certain T cells) after Hemopurifier treatment, but more patients are needed for confidence.
Long COVID Research: Preclinical data on Hemopurifier for Long COVID presented at a major symposium, with plans for a publication soon.
Enrollment Efforts: New digital recruitment and site expansion steps are underway to accelerate trial enrollment, aiming for roughly one patient per month in Cohort 2.
Strategic Focus: Management is prioritizing core oncology and Long COVID programs due to limited resources, with possible future expansion if funding allows.
